FDA Drug Topics: Role of FDA and ISMP in Preventing Medication Errors
June 30, 2020
This webinar will describe the role of the Division of Medication Error Prevention and Analysis (DMEPA) in preventing and addressing medication errors through pre-market and post-market activities. DMEPA also collaborates with external stakeholders, such as the nonprofit Institute for Safe Medication Practices (ISMP), a federally authorized patient safety organization (PSO). The webinar will illustrate how information from the ISMP National Medication Errors Reporting Program is shared with FDA in a way that benefits overall drug safety. Actions taken to address recent medication error reports will be explored, as well as the role of pharmacists in identifying, preventing and mitigating medication errors.
- Draft Guidance for Industry: Best Practices in Developing Proprietary Names for Drugs: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-developing-p roprietary-names-drugs.
- Draft Guidance for Industry: Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-considerations-conta iner-labels-and-carton-labeling-design-minimize-medication-errors.
- Guidance for Industry: Safety Considerations for Product Design to Minimize Medication Errors: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-considerations-produ ct-design-minimize-medication-errors-guidance-industry.
- Guidance for Industry: Applying Human Factors and Usability Engineering to Medical Devices: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applying-human-factors-and- usability-engineering-medical-devices.
- A Lot Happens When You Report a Hazard or Error to ISMP – There’s No “Black Hole” Here! https://www.ismp.org/acute-care/medication-safety-alert-november-7-2019.
- ISMP. Start the New Year Off Right by Preventing These Top 10 Medication Errors and Hazards. https://www.ismp.org/acute-care/medication-safety-alert-january-16-2020.
- Describe FDA’s role in pre-marketing and post-marketing activities to prevent and address medication errors.
- Outline strategies aimed to increase the safe use of drug products by minimizing use error that is related to the design, naming, labeling, and/or packaging of drug products.
- Review examples of recent medication error reports.
- Summarize how HCPs can help identify, prevent, and mitigate medication errors.
This activity is intended for physicians, pharmacists, pharmacy technicians, nurses, cph - certified public health, and physician assistants.
Day 1 June 30, 2020
|1:00 - 2:00 PM||FDA Drug Topics: Role of FDA and ISMP in Preventing Medication Errors||
Mishale Mistry, PharmD
Michael Cohen, R. Ph
Physicians, physician assistants, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.
Pharmacists will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit.
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians, physician assistants, and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 10 weeks after the last session of the activity to obtain their CE credit.
- Cohen, Michael, R. Ph, President, ISMP - nothing to disclose
- Mistry, Mishale, PharmD, Associate Director, FDA - nothing to disclose
- Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose
- Cao, Christian, MPAS, PA-C, Safety Evaluator Team Leader, FDA/CDER/OSE/DPV - nothing to disclose
- DeFronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
- Kapoor, Rama, MD, Medical Officer, FDA - nothing to disclose
- Navin, Lesley, RN, MSN, Consumer Safety Officer, FDA/CDER/DDI - nothing to disclose
CE Consultation and Accreditation Team
- Lisa Thompson, MSHA, MBA, CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose
Registration is complimentary, therefore refunds are not applicable.
Must attend 80% of the activity.
- This warning banner provides privacy and security notices consistent with applicable federal laws, directives, and other federal guidance for accessing this Government system, which includes (1) this computer network, (2) all computers connected to this network, and (3) all devices and storage media attached to this network or to a computer on this network.
- This system is provided for Government-authorized use only.
- Unauthorized or improper use of this system is prohibited and may result in disciplinary action and/or civil and criminal penalties.
- Personal use of social media and networking sites on this system is limited as to not interfere with official work duties and is subject to monitoring.
- By using this system, you understand and consent to the following:
- The Government may monitor, record, and audit your system usage, including usage of personal devices and email systems for official duties or to conduct HHS business. Therefore, you have no reasonable expectation of privacy regarding any communication or data transiting or stored on this system. At any time, and for any lawful Government purpose, the government may monitor, intercept, and search and seize any communication or data transiting or stored on this system.
- Any communication or data transiting or stored on this system may be disclosed or used for any lawful Government purpose.